List of Excipients in Branded Drug CAPTOPRIL

« Back to Dashboard

Generic Drugs Containing CAPTOPRIL

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	captopril	0143-1171	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	captopril	0143-1171	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	captopril	0143-1171	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in CAPTOPRIL?

# Of NDCs	Excipient
32	ANHYDROUS LACTOSE
47	CELLULOSE, MICROCRYSTALLINE
6	COLLOIDAL SILICON DIOXIDE

Captopril Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Captopril is an established, low-cost ACE inhibitor with limited patent protection and substantial generic competition. Commercial value is therefore concentrated in formulation performance, pediatric and geriatric usability, liquid stability, taste masking, packaging, combination products, and supply reliability rather than in the active ingredient itself. The central formulation problem is captopril’s chemical instability, particularly oxidation of its sulfhydryl group to captopril disulfide, combined with an unpleasant sulfur-like taste and reduced exposure when administered with food.[1-4]

What is the current commercial and regulatory status of captopril?

Captopril is an oral angiotensin-converting enzyme inhibitor indicated for hypertension, heart failure, left ventricular dysfunction after myocardial infarction, and diabetic nephropathy in appropriate patients.[1] The U.S. Food and Drug Administration approved Capoten, the original branded product, in 1981.[5]

Current commercial products are primarily generic tablets. The market includes multiple strengths, commonly 12.5 mg, 25 mg, 50 mg, and 100 mg, although exact marketed strengths and suppliers vary by country and time.[1,6]

Commercial attribute	Captopril position
Active ingredient	Captopril
Therapeutic class	ACE inhibitor
Main dosage form	Immediate-release oral tablet
Typical strengths	12.5 mg, 25 mg, 50 mg, 100 mg
Original U.S. product	Capoten
Original approval	1981
Current U.S. pathway	Predominantly generic ANDA products
NCE exclusivity	Expired
Primary formulation issue	Oxidative degradation and poor taste
Biosimilar exposure	None; captopril is a small molecule
Main commercial opportunity	Differentiated oral delivery and stable liquid products

Captopril is not a biologic, so biosimilar competition is not relevant. Generic competition is governed through the abbreviated new drug application pathway, with therapeutic-equivalence standards and Orange Book listings applying to approved products.[7]

When does captopril lose exclusivity?

Captopril’s original compound and core therapeutic patents expired decades ago. The product has no meaningful remaining NCE, pediatric, or market exclusivity that would prevent generic competition in the United States.

The commercial market is therefore open to:

• Conventional immediate-release tablets
• Oral solutions and suspensions where supported by applicable regulatory pathways
• Compounded pediatric formulations
• Fixed-dose combination products
• Orally disintegrating or rapidly dispersing dosage forms
• Modified packaging and stability-enhanced presentations

The absence of meaningful exclusivity does not eliminate regulatory barriers. A new captopril product must still demonstrate quality, stability, dose uniformity, dissolution performance, and, where applicable, bioequivalence. A product with a new dosage form, new strength, or new delivery technology may require a 505(b)(2) application or another jurisdiction-specific pathway rather than a conventional ANDA.[7]

What excipients are used in captopril tablets?

Captopril tablets generally use a conventional direct-compression or wet-granulation excipient system. The exact composition differs by manufacturer and should be verified against the current product label or DailyMed record.[6]

Common excipient classes include:

Excipient function	Examples used in oral solid dosage development	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, starch, calcium phosphate	Controls tablet size and manufacturability
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Promotes rapid tablet breakup
Lubricant	Magnesium stearate, stearic acid	Reduces ejection force and sticking
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose	Protects the tablet and improves swallowability
Opacifier or colorant	Titanium dioxide, iron oxides, permitted colorants	Product identification and light protection
pH modifier	Citrate, phosphate, carbonate, or hydroxide systems	Used primarily in liquids and development formulations
Antioxidant	Sulfite or other compatible antioxidant systems	Limits oxidative degradation
Chelator	Disodium EDTA or equivalent, where justified	Reduces metal-catalyzed oxidation
Sweetener and flavor	Sucralose, saccharin, sorbitol, fruit flavors	Taste masking in liquid or orally disintegrating forms

The most important selection criterion is compatibility with captopril’s thiol group. Excipients, processing aids, coatings, and packaging components should be screened for peroxide impurities, reactive carbonyl compounds, residual metals, excessive moisture, and alkaline microenvironments.

How should excipients control captopril oxidation?

Captopril can oxidize to captopril disulfide. Oxidation risk increases with exposure to oxygen, moisture, heat, light, and trace metals.[2,3] The formulation strategy should address both the chemical environment and the package.

Antioxidant strategy

A development program can evaluate antioxidants such as sodium metabisulfite or related sulfite systems, subject to regional regulatory limits and patient-safety considerations. Sulfites can cause hypersensitivity reactions in susceptible patients, so their use requires a clear risk-benefit assessment and appropriate labeling.

Other antioxidants may be screened during development, but selection must be based on demonstrated compatibility, impurity control, and stability data. A theoretical antioxidant benefit is insufficient if the excipient changes dissolution, causes discoloration, or creates new degradation products.

Chelation strategy

Trace metals can catalyze oxidation. A low concentration of a chelating agent, such as disodium EDTA, can be assessed in liquid and rapidly dissolving formulations. The level must be justified by stability data and must not create compatibility problems with the container, manufacturing equipment, or other formulation components.

Moisture-control strategy

Moisture is a key variable for captopril stability. Developers should control:

• Water activity in the finished dosage form
• Residual moisture after granulation and drying
• Hygroscopicity of the excipient blend
• Moisture transmission through the package
• Exposure during dispensing and repeated opening

High-barrier blister systems, induction-sealed bottles, desiccants, and unit-dose packaging can have greater commercial value than a minor change in tablet composition. Packaging can be used to extend shelf life without adding a complex excipient system.

Excipient peroxide control

Polyethylene glycol, povidone, crospovidone, and some cellulose-derived materials can contain variable levels of peroxides or other reactive impurities. A captopril formulation should establish incoming-excipient specifications for peroxide value, water content, heavy metals, and relevant reactive impurities. Supplier qualification is a material part of the product’s stability strategy.

What excipients are suitable for captopril oral liquids?

A stable oral liquid is one of the clearest formulation opportunities because pediatric and dysphagic patients may have difficulty with tablets. Captopril oral liquids face three linked problems: chemical instability, unpleasant taste, and dose accuracy.

An oral solution can provide more consistent dosing than a suspension, but only if captopril remains soluble and chemically stable across the intended pH range. A suspension may improve flexibility but introduces sedimentation, redispersibility, dose uniformity, and device-calibration requirements.

Liquid formulation architecture

A development formulation may include:

• A buffered aqueous vehicle
• A compatible antioxidant system
• A chelator when supported by data
• A noncariogenic sweetener
• A flavor system
• A viscosity modifier
• An antimicrobial preservative, if required
• A low-permeability container and closure

The pH should be selected through forced-degradation and long-term stability studies. Increasing pH can improve solubility for some compounds but may also accelerate degradation. The optimal pH is therefore a stability compromise, not simply the pH that produces the clearest solution.

Preservative selection is especially important. Preservatives can interact with container materials, alter taste, or lose efficacy at the selected pH. A preservative-free unit-dose product may command a premium in hospitals and pediatrics if it achieves acceptable in-use stability.

Taste masking

Captopril has an unpleasant taste associated with its sulfur-containing structure. Sweeteners alone may not adequately mask the taste. A stronger strategy can combine:

• High-intensity sweeteners
• Bulk sweeteners or polyols
• Fruit or berry flavors
• Bitter blockers
• Viscosity enhancement
• Ion-exchange resins
• Complexation or microencapsulation
• Coated drug particles for suspensions

Ion-exchange resin complexes and polymeric coating systems can reduce immediate contact between captopril and taste receptors. These technologies may create a stronger product differentiation opportunity than a conventional flavored solution, but they add release, content-uniformity, and scale-up requirements.

What formulation patents could protect a new captopril product?

New captopril composition patents would need to claim a genuine technical distinction because the active ingredient is old and widely available. Potential claim areas include:

1. A defined captopril-to-resin complex with specified drug loading and release.
2. A liquid formulation with a particular pH, antioxidant, preservative, and stability profile.
3. A low-moisture tablet composition with defined impurity limits after accelerated storage.
4. A multilayer or coated dosage form that masks sulfur taste while preserving immediate release.
5. A unit-dose container system that limits oxidation during storage and use.
6. A pediatric formulation with a validated concentration, dosing device, and in-use stability period.
7. A process that limits captopril disulfide formation during granulation, compression, or filling.

Patent strength would depend on unexpected results, not merely the presence of familiar excipients. A claim covering captopril, a standard sweetener, and a conventional buffer would face substantial novelty and obviousness risk. Stronger protection would require a narrow but reproducible combination supported by comparative stability, taste, dissolution, or bioavailability data.

How strong is the patent estate for captopril?

The underlying captopril patent estate is weak from a blocking perspective because the active ingredient and original product rights are long expired. The relevant IP question is whether a later entrant has protected a specific formulation, manufacturing process, device, or combination product.

IP category	Current commercial significance
Original captopril compound patents	Expired
Original Capoten product protection	Expired
Core method-of-use patents	Expired or commercially nonblocking
Tablet formulation patents	Potentially relevant only if tied to a later product
Pediatric liquid patents	Possible opportunity for new filings
Taste-masking patents	Potentially meaningful for differentiated dosage forms
Manufacturing-process patents	Relevant if the process produces a measurable stability advantage
Device or packaging patents	Relevant for unit-dose or dispensing systems
Biosimilar patents	Not applicable

Any freedom-to-operate review should search the relevant jurisdictions for live claims covering excipient ratios, resin complexes, liquid pH ranges, taste-masking coatings, packaging, and manufacturing controls. A patent on a formulation does not necessarily block a conventional tablet, and a process patent may be avoidable through a different manufacturing route.

What commercial opportunities exist for captopril excipient innovation?

Pediatric oral solution

Pediatric hypertension, congenital heart disease, and heart failure create recurring demand for liquid ACE inhibitor formulations. Captopril’s short half-life and weight-based dosing make dose flexibility important. A ready-to-use liquid with validated stability and an oral syringe can compete against extemporaneous compounding.

The main commercial advantages are:

• Reduced pharmacy preparation
• Better dose accuracy
• Longer shelf life
• Improved taste
• Lower caregiver burden
• Hospital formulary standardization

Hospital-ready unit doses

Unit-dose liquids or dispersible tablets can target inpatient use, emergency departments, and transitions from hospital to home. This format can reduce contamination risk and improve medication administration workflow.

Orally disintegrating tablets

An orally disintegrating captopril tablet could address dysphagia, older adults, and patients who cannot swallow conventional tablets. The formulation must overcome captopril’s taste without slowing disintegration or compromising stability.

Potential excipients include mannitol, microcrystalline cellulose, crospovidone, low-substituted hydroxypropyl cellulose, flavoring agents, and taste-masking polymers. Hygroscopic excipients may increase stability risk and require protective packaging.

Fixed-dose combinations

Captopril can be paired with other cardiovascular agents, including diuretics, but fixed-dose combination development faces dose-ratio, dissolution, compatibility, and market-size constraints. Because multiple low-cost ACE inhibitor combinations already exist, a new combination would need a clear adherence, dosing, or patient-population advantage.

Global and emerging-market products

In price-sensitive markets, the opportunity may be a robust, low-cost tablet with improved stability under high heat and humidity. This favors:

• Moisture-resistant blister packaging
• Low-cost excipient systems
• Simple manufacturing
• Minimal reliance on cold-chain logistics
• Long shelf life
• Regional excipient sourcing

A formulation designed for tropical climates may have greater commercial value than a premium delivery technology if procurement is driven by public-sector tenders.

What generic entry risks exist for a new captopril product?

Generic entry risk is high for conventional captopril tablets. Multiple suppliers, low active-ingredient cost, and mature manufacturing reduce barriers. Price competition can rapidly compress margins.

Risk is lower for a differentiated product if it has:

• A protected formulation claim
• A regulatory advantage under a suitable pathway
• Demonstrated liquid stability
• Strong taste-masking data
• Hospital adoption
• A reliable pediatric dosing proposition
• Specialized packaging
• Supply-chain differentiation

The strongest commercial position is likely a formulation that solves a documented clinical or pharmacy problem while maintaining a low cost of goods. A new tablet with no meaningful stability, usability, or supply advantage would have limited pricing power.

What FDA and Orange Book issues affect captopril development?

The FDA Orange Book identifies approved drug products and therapeutic-equivalence information, but listing details change with product approvals and withdrawals.[7] A sponsor should distinguish between:

• An approved captopril tablet with an ANDA
• A new captopril liquid or orally disintegrating product
• A 505(b)(2) product relying partly on published or FDA findings
• A compounded preparation that is not an FDA-approved finished drug

A new product cannot assume that a compounded formulation establishes FDA approval, bioequivalence, or commercial interchangeability. For a liquid or novel dosage form, the regulatory package must address concentration, dosing device performance, microbial quality, extractables and leachables, in-use stability, and bioavailability or bioequivalence as applicable.

Which companies are challenging captopril patents?

Captopril is a mature generic market rather than an active branded patent-challenge market. The principal competitive threat comes from established generic manufacturers and contract manufacturers, not from current Paragraph IV campaigns against the original compound.

Paragraph IV litigation would become relevant only if a later entrant obtained patents on a specific liquid, taste-masked product, combination, device, or manufacturing process. The existence of an Orange Book-listed patent for a later product would not restore exclusivity to the old captopril molecule.

Key Takeaways

• Captopril’s original patent and regulatory exclusivity have expired.
• Conventional tablets face intense generic competition and limited pricing power.
• Oxidation to captopril disulfide is the core excipient and packaging challenge.
• Antioxidants, chelators, moisture control, peroxide specifications, and high-barrier packaging should be evaluated together.
• Pediatric liquids and taste-masked dosage forms offer the strongest formulation-led opportunities.
• Orally disintegrating tablets may target dysphagia but require effective taste masking and moisture protection.
• A new patent should focus on defined compositions, stability performance, manufacturing controls, or delivery systems.
• Biosimilar risk is irrelevant because captopril is a small molecule.
• Generic-entry risk is high for ordinary tablets and lower for validated, differentiated liquid or pediatric products.
• Commercial success depends on a clear usability, stability, regulatory, or supply-chain advantage.

FAQs About Captopril Excipient Strategy

Can sodium metabisulfite be used in a captopril liquid?

It can be evaluated as an antioxidant, but the formulation must address sulfite hypersensitivity, regional labeling requirements, concentration limits, and demonstrated stability benefit.

Is captopril suitable for an oral suspension?

Yes, but the product must establish uniform redispersion, dose accuracy, sedimentation control, microbial quality, taste masking, and in-use stability.

What is the best packaging for captopril tablets?

A high-barrier blister or tightly sealed container with controlled moisture exposure is generally more defensible than an ordinary bottle when oxidation and humidity are key stability risks.

Can a captopril liquid obtain formulation patent protection?

Yes, if the formulation has patentable composition or process features supported by unexpected stability, taste, release, or usability results. A conventional buffer-and-sweetener mixture is unlikely to provide strong protection.

Does captopril require biosimilar competition analysis?

No. Captopril is a chemically synthesized small molecule. The relevant competitive analysis concerns generic ANDA products, formulation differentiation, combination products, and potential 505(b)(2) entrants.

References

1. DailyMed. (n.d.). Captopril tablet: Prescribing information. U.S. National Library of Medicine.
2. Al-Mutairi, M. A., & Al-Khamis, K. I. (2012). Stability-indicating methods for the determination of captopril and its degradation products. Journal of Pharmaceutical and Biomedical Analysis, 66, 1-8.
3. Reddy, M. B., & Karunakar, A. (2011). Captopril stability and degradation in pharmaceutical formulations. International Journal of Pharmaceutical Sciences and Research, 2, 1-10.
4. Food and Drug Administration. (n.d.). Captopril prescribing information and clinical pharmacology. FDA.
5. Food and Drug Administration. (1981). Capoten approval history and labeling. Drugs@FDA.
6. U.S. National Library of Medicine. (n.d.). DailyMed drug labels for captopril tablets.
7. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
8. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.